Leukocyte glucose index as a novel biomarker for COVID-19 severity

Leukocyte glucose index as a novel biomarker for COVID-19 severity

The severity of coronavirus disease 2019 (COVID-19) quickly progresses with unfavorable outcomes due to the host immune response and metabolism alteration. Hence, we hypothesized that leukocyte glucose index (LGI) is a biomarker for severe COVID-19. This study involved 109 patients and the usefulnes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2022-09, Vol.12 (1), p.14956-10, Article 14956
Hauptverfasser: Ramos-Hernández, Wendy Marilú, Soto, Luis F., Del Rosario-Trinidad, Marcos, Farfan-Morales, Carlos Noe, De Jesús-González, Luis Adrián, Martínez-Mier, Gustavo, Osuna-Ramos, Juan Fidel, Bastida-González, Fernando, Bernal-Dolores, Víctor, del Ángel, Rosa María, Reyes-Ruiz, José Manuel
Format: Artikel
Sprache:eng
Schlagworte:
631/326
631/326/596
692/53/2423
Biomarkers
COVID-19 - diagnosis
Female
Glucose
Glycemic Index
Humanities and Social Sciences
Humans
Leukocytes
Male
multidisciplinary
Science
Science (multidisciplinary)
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The severity of coronavirus disease 2019 (COVID-19) quickly progresses with unfavorable outcomes due to the host immune response and metabolism alteration. Hence, we hypothesized that leukocyte glucose index (LGI) is a biomarker for severe COVID-19. This study involved 109 patients and the usefulness of LGI was evaluated and compared with other risk factors to predict COVID 19 severity. LGI was identified as an independent risk factor (odds ratio [OR] = 1.727, 95% confidence interval [CI]: 1.026–3.048, P  = 0.041), with an area under the curve (AUC) of 0.749 (95% CI: 0.642–0.857, P  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-18786-5